Warning letter
Hillestad Pharmaceuticals USA, Inc.: warning letter of Apr 17, 2013
FDA warning letter 360978 · Minneapolis District Office
Key facts
| Reference number | 360978 |
|---|---|
| Company | Hillestad Pharmaceuticals USA, Inc. |
| Subject | CGMP/Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements/Adulterated |
| Issue date | Apr 17, 2013 |
| Posted date | Apr 17, 2013 |
| Issuing office | Minneapolis District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 111, 111.210, 111.75(h)(1), 111.210(h)(2), 111.210(h)(5), 111.75(c), 111.75(c)(3) |
| Inspection city | Woodruff |
| Inspection ZIP | 54568 |
| Inspection start date | May 25, 2012 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: